As scientific research continues to generate new disease insights, we believe it is critical to ensure that these discoveries are accessible to patients. Our expertise and capabilities are specifically tailored to translate scientific research into investigational medicines.
Making Medicines
Treatments that matter
Our pipeline
We’re advancing a broad pipeline of drug and diagnostic candidates, independently and in collaboration with partners, with demonstrated potential to improve people’s lives.
Peptide therapeutic for obesity
Small-molecule therapeutic for metabolic disease
Pediatric rare diseases
Learn more
Therapeutic antibodies
Protein degrader
Alzheimer’s disease
Learn more
Small-molecule therapeutics for Alzheimer’s disease
Astrocyte-targeted therapeutic for Alzheimer’s disease
Libris Innovations extends IBRI’s impact by supporting new startup companies with the mission of advancing our pioneering technologies, therapeutics, and diagnostics toward commercialization. Our goal is to grow a robust life sciences innovation ecosystem around IBRI with strong ties to investors, industry partners, and patients.
Learn More
